Short answer
ACCENDRA HEALTH INC/VA/ (ACH) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Receivables securitization extended through October 2029, preserving a longer-term funding source for working capital.
ACCENDRA HEALTH INC/VA/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Receivables securitization extended through October 2029, preserving a longer-term funding source for working capital
- Revised account-control provisions and reporting obligations, potentially increasing administrative and compliance requirements
- PNC remains administrative and structuring agent, indicating continued banking support for the program
- Amendment supports liquidity flexibility but does not disclose changes to borrowing capacity, pricing, or outstanding obligations
Item 7.01 · Regulation FD Disclosure
- Press release issued November 2, 2026, covering the foregoing company event
- Exhibit 99.1 contains the substantive disclosure and is the key investor document
Item EX-99.1 · Exhibit EX-99.1
- $150 million receivables sale program extended to October 2029
- Facility size unchanged, preserving an existing liquidity source
- Extension indicates continued banking-partner support for Accendra’s receivables portfolio
- Amendment executed October 29, 2026, extending financing availability by three years
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACCENDRA HEALTH INC/VA/ 8-K filings
Get the next ACH 8-K as it lands
Follow ACH for push alerts, or ask the research agent what this filing means.